<DOC>
	<DOCNO>NCT01103011</DOCNO>
	<brief_summary>The study hypothesis continuous ND0611 increase bioavailability levodopa therefore levodopa area-under-the-concentration-curve value , half-life , trough concentration The study help determine safety tolerability ND0611 determine pharmacokinetic profile levodopa follow multiple oral dosing levodopa/carbidopa ( LD/CD ) continuous delivery ND0611</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetic Profile Levodopa Administered With Continuous Administration ND0611</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Healthy Caucasian male 18 50 year ( inclusive ) age Normal body weight Subjects negative urinary drug abuse , HIV , Hepatitis B Hepatitis C serology test Subjects must able adhere protocol requirement Subjects must provide write informed consent participate study . Haemoglobin level &gt; 12.5 mg /dl History significant psychiatric disorder , neurological disease sleep disorder History significant systemic disease , medical history test perform screen examination Clinically significant laboratory test screen History drug alcohol abuse . Allergy levodopa , carbidopa inactive component test formulation . Subjects dark skin Subjects skin disease neoplasms Subjects narrowangle glaucoma Subjects significant allergic response drug . Subject known atopic disorder Known allergy hypersensitivity adhesive tape . Use prescription overthecounter ( OTC ) medication Subjects donate blood receive blood , last 3 month Participation another clinical trial last 30 day Subjects ability communicate well adhere protocol procedure</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2010</verification_date>
</DOC>